Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Insulin Lispro vial (Admelog vial)

<u>Initiation (new start) criteria:</u> Non-formulary **insulin lispro 100 units/mL vial** (**Admelog vial**) will be covered on the prescription drug benefit for when the following criteria are met:

 The member has a documented allergic reaction to an inactive ingredient in Humalog AND unbranded biologic insulin lispro that is not present in Admelog

-AND-

Meets 1 of the following clinical criteria:

- Diagnosis of Type 1 diabetes mellitus -OR-
- On insulin pump therapy -OR-
- Use while pregnant -OR-
- Diagnosis of Type 2 diabetes mellitus and insulinopenia* -OR-
- Patients with Type 2 diabetes mellitus who require intensive glycemic control (4 or more insulin injections per day) AND have recurrent hypoglycemia with regular insulin defined as 3 or more episodes of low blood sugar (less than 70 mg/dL) over the preceding 30 days that persists despite regular insulin dose adjustments

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary insulin lispro
100 units/mL vial (Admelog vial) will be covered on the prescription drug benefit for when the following criteria are met:

 The member has a documented allergic reaction to an inactive ingredient in Humalog AND unbranded biologic insulin lispro that is not present in Admelog

-AND-

kp.org

Revised: 04/14/22 Effective: 06/02/22 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



^{*} Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE


Insulin Lispro vial (Admelog vial)

Meets 1 of the following clinical criteria:

- · Diagnosis of Type 1 diabetes mellitus -OR-
- On insulin pump therapy -OR-
- Use while pregnant -OR-
- Diagnosis of Type 2 diabetes mellitus and insulinopenia* -OR-
- Patients with Type 2 diabetes mellitus who require intensive glycemic control (4 or more insulin injections per day) AND have recurrent hypoglycemia with regular insulin defined as 3 or more episodes of low blood sugar (less than 70 mg/dL) over the preceding 30 days that persists despite regular insulin dose adjustments

kp.org

Revised: 04/14/22 Effective: 06/02/22





All plans offered and underwritten by

^{*} Insulinopenia is defined as a fasting c-peptide level of 0.88 ng/mL or less with a concurrent glucose of 70-225 mg/dL OR in patients with renal insufficiency (creatinine clearance of 50 mL/min or less), a fasting c-peptide level of 1.6 ng/mL or less with a concurrent glucose of 70-225 mg/dL.